# Optimi Health Corp. (OPTH)

Source: https://www.quantisnow.com/company/OPTH
Generated: 2026-11-09T03:05:06.914Z

- Ticker: OPTH
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0002027329

## About

Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) is a commercial-stage pharmaceutical company focused on developing, manufacturing, and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facility in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorised Prescriber Scheme and accessible in Canada through the Special Access Program. The Company plans to advance a Health Canada-approved Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder and a proposed Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder.

## Latest OPTH news and filings

No events on the wire yet.

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OPTH
- Earnings history: https://www.quantisnow.com/earnings/OPTH
- Dividend history: https://www.quantisnow.com/dividends/OPTH
- Insider transactions: https://www.quantisnow.com/insiders/OPTH
- Options chain: https://www.quantisnow.com/options/OPTH
- SEC 8-K filings only: https://www.quantisnow.com/company/OPTH/8-k
- RSS and alerts for OPTH: https://www.quantisnow.com/docs/rss-feeds.md